AgingResearch.NewsJoin free

MBA-159

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Agencia Estatal de Investigación and 8 more
  • Animals1

Outcomes

2

Cognitive function

upin mice1

1 study

  1. MBA-159 improves cognitive function in mice.

    “as well as cognitive enhancement in a senescence-accelerated prone mouse 8 model.”

    Animalssenescence-accelerated prone mouse 8 model

    N-Methyl-N-((1-methyl-5-(3-(piperidin-1-yl)propoxy)-1H-benzo[d]imidazol-2-yl)methyl)prop-2-yn-1-amine (MBA-159), a new multitarget small molecule for the therapy of Alzheimer's disease

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie27 Sep 2025

Non-spatial memory

upin mice1

1 study

  1. MBA-159 improves non-spatial memory in mice.

    “significantly improved non-spatial memory (contextual and recognition memory) in a mouse model of scopolamine-induced amnesia.”

    Animalsscopolamine-induced amnesia

    N-Methyl-N-((1-methyl-5-(3-(piperidin-1-yl)propoxy)-1H-benzo[d]imidazol-2-yl)methyl)prop-2-yn-1-amine (MBA-159), a new multitarget small molecule for the therapy of Alzheimer's disease

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie27 Sep 2025

Latest

Related